Cardiac action potentials are one of those “if you can table it, you can ace it” topics: Step questions love to swap one ion current or phase and ask you to predict the EKG change, drug effect, or arrhythmia risk. This post gives you a quick-hit comparison table, plus a sticky mnemonic/visual so you can recall which cells have which phases, which channels matter, and what drugs do.
The two big categories you must separate
1) Fast-response AP (non-nodal)
Cells: atrial myocytes, ventricular myocytes, Purkinje fibers
Defining feature: rapid phase 0 upstroke via fast channels → fast conduction
2) Slow-response AP (nodal)
Cells: SA node, AV node
Defining feature: no true resting potential + slow phase 0 via channels → slower conduction, physiologic delay
Visual/Mnemonic Device (shareable)
“W-shaped vs ramp-shaped”
- Working myocytes/Purkinje: think W = 0–1–2–3–4 (you see the notch + plateau)
- Nodal cells: think ramp = 4 → 0 → 3 (no phases 1 or 2)
One-liner that usually gets you the point
“Myocytes shoot up with and plateau with ; nodes drift up with funny and fire with .”
Comparison Table: Cardiac Action Potentials (High-Yield)
| Feature | Atrial/Ventricular Myocytes (Fast) | Purkinje (Fast) | SA/AV Node (Slow) |
|---|---|---|---|
| Primary job | Contractile force | Fast conduction backup pacemaker | Pacemaker + AV delay |
| Resting membrane potential | Stable ~ −85 to −90 mV | Stable ~ −90 mV | Unstable (no true resting potential) |
| Phase 0 (upstroke) | Fast influx (voltage-gated) | Fast influx (very fast conduction) | influx (L-type) |
| Phase 1 (early repol) | Transient out (Ito) | Present | Absent |
| Phase 2 (plateau) | in (L-type) balanced by out | Prominent/long plateau | Absent |
| Phase 3 (repol) | out (delayed rectifier) | out | out |
| Phase 4 | Flat resting potential (IK1) | Flat resting potential (IK1) | Spontaneous depolarization via If + |
| Automaticity | No (normally) | Yes (latent) | Yes (primary pacemaker SA) |
| Key “pacemaker” current | N/A | Minor | If (“funny”) = slow inward (HCN channels) |
| Most sensitive to ischemia | Ventricular myocardium (arrhythmias) | Purkinje can trigger ectopy | AV node (conduction blocks) |
| Conduction velocity | Fast (via ) | Fastest in heart | Slow (via ) |
| Refractory period purpose | Prevent tetany + allow filling | Prevent reentry + coordinate | Control rate + protect ventricles |
Phase-by-Phase: What ions are doing what?
Fast-response cells (0–1–2–3–4)
- Phase 0: in (fast channels) → steep upstroke = fast conduction
- Phase 1: brief out
- Phase 2: in (L-type) balances out → plateau
- High-yield link: plateau = long refractory period
- Phase 3: out dominates → repolarization
- Phase 4: stable resting potential (mostly conductance)
Nodal cells (4–0–3)
- Phase 4 (pacemaker):
- If (funny) current = slow inward as membrane becomes more negative
- plus T-type late in phase 4 helps reach threshold
- Phase 0: L-type influx (not ) → slow upstroke
- Phase 3: efflux → repolarization
The “USMLE trigger points” (what questions usually test)
1) What sets heart rate?
- Slope of phase 4 in SA node
- Steeper slope = faster HR
- Flatter slope = slower HR
2) What sets AV nodal conduction speed?
- Phase 0 upstroke in AV node depends on
- So anything that blocks L-type channels slows AV conduction.
3) What sets ventricular conduction speed?
- Phase 0 in myocytes depends on fast channels
- So class I antiarrhythmics widen QRS (slower ventricular depolarization).
Drug hooks you should attach to phases (super testable)
Beta-1 stimulation (sympathetic)
- SA/AV node: ↑ cAMP → ↑ If and ↑ currents
- Steeper phase 4 → ↑ HR
- ↑ AV conduction (shorter PR)
Beta blockers
- SA/AV node: ↓ cAMP → ↓ If and ↓
- Flatter phase 4 → ↓ HR
- ↓ AV conduction (longer PR)
Non-dihydropyridine CCBs (verapamil, diltiazem)
- AV node: block L-type channels
- Slower phase 0 in nodes → prolong PR, treat AVN-dependent SVTs
Class III antiarrhythmics (K+ channel blockers)
- Prolong phase 3 repolarization in fast-response tissue
- ↑ action potential duration and ↑ refractory period
- High-yield adverse effect: torsades de pointes risk via QT prolongation
High-yield mini table: “Which phase is the drug hitting?”
| Drug/Class | Cell type most tested | Main phase effect | Classic clue |
|---|---|---|---|
| Class I ( blockers) | Ventricular/Purkinje | ↓ slope of phase 0 | Wide QRS |
| Class III ( blockers) | Ventricular/Purkinje | Prolong phase 3 | Long QT ± torsades |
| Class IV (non-DHP CCBs) | AV node | ↓ phase 0 (nodal) | Long PR, AV block risk |
| Beta blockers | SA/AV node | ↓ phase 4 slope | ↓ HR, long PR |
| Adenosine | AV node | ↑ out, ↓ in | “Stops” AVN-dependent SVT (very short half-life) |
Rapid-fire one-liners to memorize
- “Plateau = calcium = refractory.” (Phase 2 in myocytes)
- “Nodes use calcium for phase 0.” (So CCBs/beta blockers hit AV conduction)
- “Funny current is sodium… but it’s weird sodium.” (If in phase 4)
- “ channels determine ventricular conduction; channels determine AV nodal conduction.”
Quick self-check (30 seconds)
- If you block L-type channels, which interval changes most? → PR increases (AV node slows)
- If you block fast channels, what happens to QRS? → QRS widens
- If you prolong phase 3, what EKG change do you expect? → QT prolongation (torsades risk)